Related Experiment Video
Updated: Sep 18, 2025
09:43
Synthesis of Immunotargeted Magneto-plasmonic Nanoclusters
Published on: August 22, 2014
15.4K
Antibody-conjugated nanoparticles for therapeutic applications
M M Cardoso1, I N Peça, A C A Roque
1Requimte, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2825 Monte de Caparica, Portugal. mmcmac@fct.unl.pt
Current Medicinal Chemistry
|May 23, 2012
Summary
Antibody-conjugated nanoparticles enhance chemotherapy delivery, targeting diseased sites to minimize side effects. This approach improves drug accumulation and overcomes multi-drug resistance for treating serious diseases.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Pharmacology
Background:
- Chemotherapy faces challenges in targeted delivery, leading to severe toxic effects and limited therapeutic index.
- Off-target side effects and multi-drug resistance (MDR) mediated by P-glycoprotein hinder effective cancer treatment.
- Nanoparticles offer a platform for drug delivery, but targeted strategies are needed to improve efficacy.
Purpose of the Study:
- To review recent advancements in antibody-conjugated nanoparticles for active drug targeting.
- To explore the potential of these nanocarriers in overcoming physiological barriers and enhancing drug accumulation.
- To summarize the therapeutic opportunities of antibody-functionalized nanoparticles in treating major diseases.
Main Methods:
- Review of literature on antibody engineering and nanoparticle functionalization.
- Analysis of nanoparticle-mediated drug delivery mechanisms, including receptor-mediated endocytosis.
- Exploration of nanoparticle interactions with biological barriers and drug resistance mechanisms.
Main Results:
- Antibody-conjugated nanoparticles combine nanoparticle advantages with antibody specificity for targeted delivery.
- These nanocarriers can encapsulate multiple chemotherapeutic agents and overcome biological barriers.
- Internalization via receptor-mediated endocytosis and evasion of P-glycoprotein enhance intracellular drug concentration and overcome MDR.
Conclusions:
- Antibody-conjugated nanoparticles represent a promising strategy for targeted drug delivery in various diseases.
- Functionalized nanoparticles offer improved therapeutic index and reduced toxicity compared to conventional chemotherapy.
- Further development in antibody engineering and nanoparticle design will expand their therapeutic applications.
